leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 12:30:26 - browse：245

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Roche to buy Carmot Therapeutics, developer of obesity drugs

hotspot

WSS

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Supreme Court wrestles with OxyContin maker's bankruptcy deal

What PEPFAR has meant on the ground in Ukraine

Americans' trust in science, scientist continues decline: Report

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Roche to buy Carmot Therapeutics, developer of obesity drugs

Wildfire smoke exposes gaps in outdoor worker protections

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Psychedelics group wrestles with new pharma identity

Pharma patents targeted by Biden in move to slash drug prices

Malaria cases in Florida and Texas: Here’s what you need to know

Spinal cord stimulation reduces pain in amputees, study finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

focus

California Joshua trees severely burned in massive wildfire

Leukemia patients are helped by Syndax's new type of therapy

Lifetime voting ban for felony convictions struck down in Mississippi

CMS should re

Patients' immediate access to test results puts radiologists in a bind

Russian court extends detention of American musician

leisure time

hotspot

leisure time

hotspot